Look back at pharma news to Mar 10
Political news regarding healthcare and repeal of Obamacare with a planned replacement took a back seat last week, as the issue continued to be debated but with no outcome as yet. And in the UK, there were no developments on Brexit, though the Prime Minister is expected to push the Brexit button this week, which will start the ‘divorce’ negotiations. Pharma company focus included AbbVie and its Humira, Vertex and Concert Pharma, TG Therapeutics and Kite.
AbbVie under pressure in the severe plaque psoriasis space
AbbVie continues to come under pressure from competitors and this time it comes in the form of Johnson & Johnson's Janssen division with its monoclonal antibody for treating severe plaque psoriasis, noted blogger “Abba’s Aces” on Seeking Alpha. AbbVie's Humira is currently used to treat the disease and with this article I'll parse through the data to see if AbbVie remains a hold.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze